Method of use of cytokine ZALPHA11 ligand
US8110180B2 · kind B2 · utility
17Cited by
5References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2006 |
| Grant date | Feb 7, 2012 |
| Priority date | — |
| Expiry date | Jun 9, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.